[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Michigan Rogel Cancer Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":557},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,44,72,95,106,132,158,179,199,218,242,266,289,310,331,353,374,395,417,435,454,476,496,518,540],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053317","transcranial-direct-current-stimulation-for-the-treatment-of-chemotherapy-induced-peripheral-neuropathy-in-cancer-survivors-100053317",false,"NCT07673614","Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors","Improving Sensorimotor Function in CIPN: A Randomized, Sham Controlled, Double Blinded, Crossover Mechanistic Trial of Transcranial Direct Current to the Sensorimotor Cortex","Inclusion Criteria:\n\n* 18 to 85 years of age\n* Diagnosis of cancer, stages I-IV\n* Cancer survivor (not currently receiving chemotherapy, radiation, or immunotherapy)\n* Presence of CIPN defined as new, length-dependent numbness, tingling, and\u002For pain that developed with neurotoxic chemotherapy\n* CIPN20 score ≥ 20\n* Able to walk unassisted\n* Proficient in English\n\nExclusion Criteria:\n\n* Known brain metastases\n* Known neurological conditions aside from chemotherapy-induced peripheral neuropathy (CIPN)\n* History of brain or spinal surgery\n* Neuropathy other than CIPN\n* Significant hearing or vision deficits\n* Vestibulopathy\n* Currently receiving chemotherapy, radiation therapy, or immunotherapy\n* Contraindications to transcranial direct current stimulation (tDCS), including recent seizures\n* Presence of metallic objects in the head\n* Presence of specific implanted medical devices (e.g., deep brain stimulator, cochlear implant, vagus nerve stimulator, spinal cord stimulator, pacemakers, and intracardiac devices)\n* Active scalp dermatological conditions","ALL","18 Years","85 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemotherapy as a result of changes to the nerves. A non-invasive form of brain stimulation called tDCS, applied to the area of the brain involved in sensation and movement, can temporarily improve the ability to detect vibration and temperature, as well as balance and walking, which may improve sensation and reduce pain in cancer survivors with CIPN.",[28,29,30],"Chemotherapy-Induced Peripheral Neuropathy","Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm","NOT_YET_RECRUITING","2026-07-09",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":22},"2026-08-01",{"date":39,"type":22},"2028-02",{"name":41,"class":42},"University of Michigan Rogel Cancer Center","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100453329","phase-4-pharmacokinetic-study-of-skeletal-muscle-area-based-paclitaxel-infusion-in-patients-with-cancer-100453329","NCT05183126","Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer","Phase IV Single-arm Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer","Inclusion Criteria:\n\n* Planned paclitaxel 80 mg\u002Fm\\^2, 1-hour infusion\n* Evaluable computed tomography (CT) scan, positron emission tomography computed tomography (PET-CT) scan, or MRI scan (e.g. scan of the chest, abdomen, or pelvis for any indication w\u002Fin 1 year)\n* Female\n* ≥ 18 years old\n* Adequate organ function to receive paclitaxel treatment as defined in the protocol\n* Ability to understand and the willingness to sign a written informed consent\n\nExclusion Criteria:\n\n* Concomitant administration of any moderate or strong inducer or inhibitor of CYP2C8, including rifampin or clopidogrel.\n* History of hypersensitivity reaction to paclitaxel or any components of paclitaxel (e.g., Cremophor EL) that precludes continued treatment with standard dose and infusion length\n* Pregnant or nursing\n* Receiving any other dose (i.e., not 80 mg\u002Fm2) or infusion rate (i.e., not 60 minute infusion) either due to toxicity during a previous cycle or any other reason","FEMALE",{"count":53,"type":22},22,[55],"PHASE4","The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low\u002Fsarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low\u002Fsarcopenic SMA normalizes the levels to those of patients with normal SMA.",[58,59,60],"Breast Cancer","Metastatic Gastric Cancer","Esophageal Cancer",[62],"pharmacokinetics","RECRUITING","2026-07-01",{"date":66,"type":35},"2026-07-02",{"date":68,"type":35},"2022-03-28",{"date":70,"type":22},"2026-11",{"name":41,"class":42},{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":93,"locationsCount":94},"100433512","localized-leiomyosarcoma-biomarker-protocol-100433512","NCT04925089","Localized Leiomyosarcoma Biomarker Protocol","Pilot Study of ctDNA and Imaging Characteristics as Biomarkers of Disease-related Outcomes in Patients With Localized Leiomyosarcoma Receiving Chemotherapy","Inclusion Criteria:\n\n* Patients with localized leiomyosarcoma (LMS) of extremity, body wall or retroperitoneum\n* Grade 2 or 3, or high-grade LMS\n* Tumor size \\>5 cm in greatest dimension\n* Primary tumor amenable to complete resection\n* There is no age requirement\n* Participant agrees to receive neoadjuvant doxorubicin and ifosfamide combination chemotherapy\n* If pre-operative radiation is administered, it must be administered after chemotherapy. Post-operative radiation may be administered\n* Archival tumor tissue (either frozen sample, tissue block containing tumor, or minimum of 4 unstained slides and 1 H\\&E stained slide) from diagnostic or pre-treatment biopsy available for study research",{"count":80,"type":22},40,"OBSERVATIONAL","* Leiomyosarcoma (LMS) is one of the more common soft tissue sarcomas (STS).\n* Patients presenting with large, high-grade, localized LMS are at significant risk of developing metastasis following curative surgery.\n* Clinical trials of neoadjuvant or adjuvant anthracycline and ifosfamide have suggested that patients with localized STS who are at high-risk of metastasis may benefit from chemotherapy, but the magnitude of benefit in unselected patient population is relatively small.\n* Currently, patient age, and tumor size and grade are used to assess risk of metastases and survival\n* Studies evaluating tumor response by imaging and histopathology have not established correlation between tumor characteristics as biomarkers for risk of metastasis or sarcoma recurrence.\n* Circulating tumor DNA (ctDNA) is present in blood of patients with advanced\u002Fmetastatic LMS and may serve as biomarker of tumor response to chemotherapy. Blood samples will be collected prior to, during and after chemotherapy and analyzed for ctDNA and for mutations in genes that are associated with increased risk of developing sarcoma. Tumor tissue will be collected and analyzed for changes in genes. Digital images of the sarcoma from CT or MRI scans obtained during treatment will be obtained for advanced radiomic analysis. Patients will be followed for 2 years after study entry for signs of sarcoma recurrence.\n* A biomarker of tumor response and patient survival benefit from chemotherapy early in the course of chemotherapy would be of significant impact in treatment planning.",[84],"Leiomyosarcoma",[86,87,88],"ctDNA","radiomics","biomarker",{"date":66,"type":35},{"date":91,"type":35},"2023-04-26",{"date":70,"type":22},{"name":41,"class":42},3,{"id":96,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":98,"briefSummary":26,"conditions":99,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":105,"locationsCount":43},"100644683",{"count":21,"type":22},[25],[28,29,30],"2026-06-24",{"date":102,"type":35},"2026-06-29",{"date":37,"type":22},{"date":39,"type":22},{"name":41,"class":42},{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":17,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":43},"100633622","personalized-cancer-support-thrive-track-to-manage-the-emotional-needs-of-young-adults-with-thyroid-melanoma-and-testicular-cancer-percs-ya-trial-100633622","NCT07529080","Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial","Personalized Cancer Support for Young Adults","Inclusion Criteria:\n\n* PARTICIPANTS RECRUITED FROM SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROGRAM (SEER)-GEORGIA: Age 18-37 at time of cancer diagnosis and age 20-39 at time of enrollment\n* PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Diagnosed with differentiated thyroid cancer (papillary or follicular thyroid cancer), melanoma, or testicular cancer at any stage and reported to the SEER-Georgia registry\n* PARTICIPANTS RECRUITED FROM SEER-GEORGIA: 2-10 years after diagnosis with cancer\n* PARTICIPANTS RECRUITED FROM SEER-GEORGIA: English speaking (able to read and speak English)\n* PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Report of any cancer-related worry (on a 5-point Likert scale from not at all to very worried; those who indicate \"not at all\" will be told the study is focused on those who experience worry)\n* PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Residing in the United States\n* PARTICIPANTS RECRUITED FROM THYROID CANCER SURVIVORS' ASSOCIATION INC. (THYCA): Age 18-37 at time of cancer diagnosis and age 20-39 at time of enrollment\n* PARTICIPANTS RECRUITED FROM THYCA: Diagnosed with differentiated thyroid cancer (papillary or follicular thyroid cancer) at any stage\n* PARTICIPANTS RECRUITED FROM THYCA: 2-10 years after diagnosis with cancer\n* PARTICIPANTS RECRUITED FROM THYCA: English speaking (able to read and speak English)\n* PARTICIPANTS RECRUITED FROM THYCA: Report of any cancer-related worry (on a 5-point Likert scale from not at all to very worried; those who indicate \"not at all\" will be told the study is focused on those who experience worry)\n* PARTICIPANTS RECRUITED FROM THYCA: Residing in the United States\n\nExclusion Criteria:\n\n* PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Subjects from certain vulnerable populations will be excluded as appropriate: fetuses, neonates, children under age 18, prisoners, institutionalized individuals, or others who may be considered vulnerable populations per the National Institutes of Health (NIH) and Office for Human Research Protections (OHRP)\n\n  * It is possible that a subject might be pregnant. Because this involves surveys and reviewing an informational website, participation should have no additional risk for a pregnant woman\n* PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Subjects that do not meet the inclusion criteria\n* PARTICIPANTS RECRUITED FROM THYCA: Subjects from certain vulnerable populations will be excluded as appropriate fetuses, neonates, children under age 18, prisoners, institutionalized individuals, or others who may be considered vulnerable populations per the National Institutes of Health (NIH) and Office for Human Research Protections (OHRP)\n\n  * It is possible that a subject might be pregnant. Because this involves surveys and reviewing an informational website, participation should have no additional risk for a pregnant woman\n* PARTICIPANTS RECRUITED FROM THYCA: Subjects that do not meet the inclusion criteria","20 Years","39 Years",{"count":116,"type":22},142,[25],"This pilot clinical trial is intended to compare the effect of a psychosocial support tool for young adult (YA)cancer survivors - including high-quality information about their cancer combined with evidence-based psychosocial support - to a support tool providing cancer-specific information alone (minus psychosocial modules). This tool, called Thrive Track, will be for YA patients aged 20-39 with thyroid, melanoma, or testicular cancer. Young adult survivors frequently experience persistent worry and distress that can interfere with coping and reduce quality of life. They are also particularly vulnerable to the emotional impact of cancer and may not have adequate support to manage these concerns. The enhanced version of Thrive Track includes personalized emotional support content and strategies designed to help patients better manage worry and distress. Adding these emotional support tools may provide greater benefit than survivorship education alone in strengthening young adult survivors' ability to manage their emotional well-being.",[120,121,122,123,124],"Differentiated Thyroid Gland Carcinoma","Malignant Testicular Neoplasm","Melanoma","Thyroid Gland Follicular Carcinoma","Thyroid Gland Papillary Carcinoma","2026-06-23",{"date":100,"type":35},{"date":128,"type":22},"2026-07",{"date":130,"type":22},"2027-08",{"name":41,"class":42},{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":142,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":43},"100600222","phase-2-ivonescimab-before-surgery-for-the-treatment-of-resectable-stage-ii-iv-head-and-neck-cancer-100600222","NCT07094685","Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer","A Phase II Study Evaluating Neoadjuvant Ivonescimab for Resectable Head and Neck Cancer","SENIOR-HN","Inclusion Criteria:\n\n* At least 18 years of age\n* PD-L1 combined positive score (CPS) \\>= 1\n* Histologically documented advanced stage mucosal HNSCC (stage II-IV), for which surgery would be recommended in routine clinical practice\n* Primary tumor is amenable to fresh biopsy or availability of archival fresh frozen primary tissue\n* Eastern Cooperative Oncology Group (ECOG) 0-1\n* Absolute neutrophil count \\> 1500 cells\u002FuL\n* Platelet count \\>= 100,000\u002FuL\n* Hemoglobin \\>= 9.0 g\u002FdL (without transfusion within 14 days prior to cycle 1, day 1)\n* Total bilirubin =\\\u003C 1.5 x institutional upper limit of normal (ULN) or =\\\u003C 3 x ULN for participants with Gilbert's disease\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\\u003C 2.5 x institutional ULN\n* Creatinine =\\\u003C 1.5 x institutional ULN OR estimated glomerular filtration rate (eGFR) value \\>= 30\u002FmL using the Chronic Kidney Disease Epidemiology (CKD-EPI) equation OR measured (OR calculated) creatinine clearance \\>= 50 mL\u002Fmin using the Cockcroft-Gault Formula\n* Urine protein \\\u003C 2+ or 24-hour urine protein quantification \\\u003C 1.0 g\n* Prothrombin time (PT) or international normalized ratio (INR) =\\\u003C 1.5 x ULN, and partial thromboplastin time (PTT) or activated (a)PTT =\\\u003C 1.5 x ULN (unless abnormalities are unrelated to coagulopathy) This applies only to patients who are not on therapeutic anti-coagulation\n\n  * For patients receiving therapeutic anti-coagulation there are no coagulation parameters for eligibility. However, patients should be on a stable dose\n* Female patients of childbearing age per institutional definition must have negative serum pregnancy test results before enrollment\n* Female patients of childbearing potential having sex with an unsterilized male partner must agree to use a highly effective method of contraception from the beginning of screening until 90 days after the last dose of ivonescimab\n* Unsterilized male patients having sex with a female partner of childbearing potential, or a pregnant or breastfeeding partner must agree to use barrier contraception (male condom) for the duration of the treatment period until 90 days after the last dose of ivonescimab. Male patients with female partners of childbearing potential must have the female partner agree to use at least 1 form of highly effective contraception for the duration of the treatment period until 90 days after the last dose of ivonescimab\n* Ability to understand and the willingness to sign a written informed consent\n* Deemed to be a candidate for trial therapy by University of Michigan providers in both Medical Oncology and Otolaryngology or Oral and Maxillofacial Surgery\n\nExclusion Criteria:\n\n* Prior radiation therapy for treatment of the current mucosal HNSCC (patients undergoing salvage resection are excluded)\n* Prior neck dissection on the side of current mucosal HNSCC\n* Major surgical procedures or serious trauma within 4 weeks prior to enrollment. Minor local procedures (excluding central venous catheterization, port implantation, and tumor biopsy) within 3 days prior to planned cycle 1, day 1\n* History of bleeding tendencies or coagulopathy and\u002For clinically significant bleeding symptoms or risk within 4 weeks prior to enrollment\n* Nasal bleeding \u002F epistaxis (bloody nasal discharge is allowed) graded as \\>= grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 within 14 days prior to registration\n* Current use of prophylactic or full-dose anticoagulants or anti-platelet agents for therapeutic purposes that is not stable prior to enrollment is not allowed. The use of full-dose anticoagulants is permitted as long as INR or aPTT is within therapeutic limits\n* Patients with a condition requiring corticosteroid therapy (\\> 10 mg prednisone\u002Fday or equivalent) within 14 days of the first dose of study drug. Exceptions: Physiologic replacement doses are allowed even if they are \\> 10 mg of prednisone\u002Fday or equivalent, as long as they are not being administered for immunosuppressive intent. Inhaled or topical steroids are permitted, provided that they are not for treatment of an autoimmune disorder\n* Patients with active, known, or suspected autoimmune disease that has required systemic therapy within 5 years of the projected enrollment date. Exceptions: Patients with vitiligo, type I diabetes mellitus, and endocrinopathies (including hypothyroidism due to autoimmune thyroiditis) only requiring hormone replacement, childhood asthma that has resolved, or psoriasis that does not require systemic treatment are permitted\n* Patients with symptomatic central nervous system (CNS) metastases, CNS metastases with hemorrhagic features, CNS metastasis \\>= 1.5 cm, CNS radiation within 7 days prior to randomization, potential need for CNS radiation within the first cycle, or leptomeningeal disease\n* Recipient of a solid organ or allogeneic stem cell transplant\n* Patients with active hepatitis B (Patients with stable or declining levels of hepatitis B deoxyribonucleic acid \\[DNA\\] by polymerase chain reaction \\[PCR\\] on appropriate anti-viral therapy with acceptable tolerability for one month prior to enrollment will not be excluded)\n* Patients with active hepatitis C (hepatitis C virus \\[HCV\\] antibody positive with HCV ribonucleic acid \\[RNA\\] levels above the lower limit of detection)\n* Known allergy or hypersensitivity to any component of the study drug or any excipients (histidine, histidine hydrochloride, sucrose, polysorbate 80 (II), and water for injection); known history of severe hypersensitivity to other monoclonal antibodies\n* Patient is breastfeeding or plans to breastfeed during study participation\n* Radiographic evidence of major blood vessel encasement with narrowing of the vessel that the investigator determines will pose a significantly increased risk of bleeding\n* Live vaccine or live attenuated vaccine received within 4 weeks prior to planned enrollment or scheduled to receive a live vaccine or live attenuated vaccine during the study period. Inactivated vaccines are permitted\n* History of non-infectious pneumonia requiring systemic corticosteroids, or current interstitial lung disease\n* Has pre-existing peripheral neuropathy that is \\>= grade 2 by CTCAE version 5\n* History of esophageal gastric varices, severe ulcers, wounds that do not heal, abdominal fistula, intra-abdominal abscesses, or acute gastrointestinal bleeding within 6 months before enrollment\n* Acute exacerbation of chronic obstructive pulmonary disease within 4 weeks before enrollment\n* History of perforation of the gastrointestinal tract and\u002For fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection) within 6 months prior to enrollment\n* Known history of human immunodeficiency virus (HIV) whose viral load is not controlled\n* Participant has active cardiovascular disease including, but not limited to:\n\n  * Thromboembolism\n\n    * Medical history of any grade arterial thromboembolic event, grade 3 and above venous thromboembolic event (as specified in NCI CTCAE 5.0)\n  * Cardiovascular disease\n\n    * Any of the following within 12 months prior to enrollment:\n\n      * Myocardial infarction\n      * Unstable angina\n      * Unstable vascular disease (eg, aortic aneurysm at risk of rupture, Moyamoya disease)\n      * Transient ischemic attack\n      * Cerebrovascular accident\n      * Hypertensive Crisis\n      * Hypertensive encephalopathy\n      * Coronary stent placement\n    * Clinically non-significant thrombosis, such as non-obstructive catheter-associated thrombus, incidental or asymptomatic pulmonary embolism, are not exclusionary\n  * Hypertension\n\n    * Uncontrolled (persistent) hypertension:\n\n      * Systolic blood pressure \\> 160 mmHg; diastolic blood pressure \\> 100 mmHg\n  * Heart failure\n\n    * Congestive heart failure (CHF), defined as New York Heart Association (NYHA) class III-IV or hospitalization for CHF within 12 months prior\n* Participant has uncontrolled illness including, but not limited to:\n\n  * Severe infection within 4 weeks prior to enrollment, including but not limited to comorbidities requiring hospitalization, sepsis, or severe pneumonia; active infection (as determined by the investigator) requiring systemic anti-infective therapy within 2 weeks prior to enrollment (excluding antiviral therapy for hepatitis B or C)\n  * Uncontrolled diabetes\n  * Ongoing or active infection (includes infection requiring treatment with antimicrobial therapy)\n  * Psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements\n  * Active bleeding diathesis requiring anticoagulant or antiplatelet therapy",{"count":141,"type":22},28,[143],"PHASE2","This phase II trial tests how well ivonescimab before surgery works in treating patients with stage II-IV head and neck cancer that can be removed by surgery (resectable). Ivonescimab is a bispecific monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A bispecific monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).",[146,147,148,149,150],"Advanced Head and Neck Squamous Cell Carcinoma","Resectable Head and Neck Squamous Cell Carcinoma","Stage II Head and Neck Cutaneous Squamous Cell Carcinoma","Stage III Head and Neck Cutaneous Squamous Cell Carcinoma","Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma",{"date":152,"type":35},"2026-06-26",{"date":154,"type":35},"2025-11-18",{"date":156,"type":22},"2030-11-01",{"name":41,"class":42},{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":94},"100533408","phase-1-gilteritinib-for-the-treatment-of-alk-nsclc-100533408","NCT06225427","Gilteritinib for the Treatment of ALK NSCLC","Phase I Study of Gilteritinib for ALK Positive Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Stage IV (American Joint Committee on Cancer \\[AJCC\\] 8th edition) non-small cell lung cancer with an oncogenic ALK fusion\n* Histologies include adenocarcinoma, squamous cell carcinoma, adenosquamous adenocarcinoma, and NSCLC NOS (not otherwise specified)\n* The presence of an oncogenic ALK fusion established from any Clinical Laboratory Improvement Act (CLIA) certified laboratory\n* The patient must belong to one of the following treatment cohorts.\n\n  * Cohort 1: Prior 1st generation ALK tyrosine kinase inhibitor (TKI) (crizotinib) and\u002For prior 2nd generation TKI (ceritinib, brigatinib, alectinib) and\u002For lorlatinib\n  * Cohort 2: Prior 1st generation ALK TKI (crizotinib) and\u002For prior 2nd generation TKI (ceritinib, brigatinib, alectinib) and\u002For lorlatinib, and platinum-doublet chemotherapy\n  * Cohort 3: Prior 1st generation ALK TK (crizotinib) and\u002For prior 2nd generation TKI (ceritinib, brigatinib, alectinib) and\u002F or lorlatinib, platinum-doublet chemotherapy, and any other number of antineoplastic agents (including immunotherapy, standard or investigational)\n* Age ≥ 18\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Absolute neutrophil count (ANC) ≥ 1500\u002FmcL\n* Platelets ≥ 100,000\u002FmcL\n* Hemoglobin ≥ 9 g\u002FdL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)\n* Measured or calculated creatinine clearance (CrCl) ≥ 50mL\u002Fmin (calculated per Cockcroft-Gault formula)\n* Serum total bilirubin ≤ 1.5 X upper limit of normal (ULN) (per institutional guidelines) OR direct bilirubin ≤ ULN for subjects with total bilirubin levels \\> 1.5 ULN\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases\n* Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases\n* Albumin ≥ 2.5g\u002FdL\n* Female subject of childbearing potential should have a negative serum pregnancy test within 21 days of enrollment prior to receiving the first dose of study medication\n* Female subjects of childbearing potential must be willing to use a highly effective method of contraception for the course of the study, through 180 days after the last dose of study medication. Note: Abstinence is acceptable, if patient documents that this is their usual lifestyle or preferred contraception method\n* Male subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 4 months after the last dose of study therapy. Note: Abstinence is acceptable, if patient documents that this is their usual lifestyle or preferred contraception method\n* Ability to swallow pills orally and per investigator's assessment, do not have any significant issues limiting absorption of drug\n* Ability to understand and the willingness to sign a written informed consent\n* Measurable disease per RECIST v1.1 criteria assessed per screening imaging\n* If a cancerous lesion is easily and safely accessible, a pre-treatment biopsy of this lesion is strongly encouraged but NOT required prior to first dose of gilteritinib. Archival or fresh tissue biopsy may be used as long as it was obtained prior to cycle 1 day 1 (C1D1)\n* At least 7 days must have elapsed since last anti-neoplastic TKI, chemotherapy, immunotherapy, or investigational agent prior to the first dose of gilteritinib\n\nExclusion Criteria:\n\n* Received palliative radiation within 7 days of enrollment\n* Received prior therapy with a FLT3 inhibitor\n* Has a concurrent active malignancy receiving interventional therapy unless it is the investigator's opinion that the concurrent active malignancy will NOT significantly impact the survival of the patient (i.e. early stage breast cancer or prostate cancer on hormonal therapy, basal cell carcinoma awaiting Moh's or other surgery and the respective interventional therapy does NOT interact or interfere with gilteritinib.\n* Has known active and symptomatic central nervous system (CNS) metastases and\u002For carcinomatous meningitis.\n\n  * Subjects with previously treated brain metastases may participate provided they are stable (clinically asymptomatic, and ≥ 2 weeks since completion of treatment) and are not using steroids for at least 7 days prior to enrollment. A repeat MRI brain is not necessary to document stability\n  * Patients with carcinomatous meningitis are excluded regardless of clinical stability\n* If a patient is found to have new\u002Fenlarging brain metastases on the screening MRI, the patient may be monitored closely and radiation could be delayed if the patient has no symptoms, there is no vasogenic edema, and there is no evidence of midline shift.\n\n  * If the patient is symptomatic, there is vasogenic edema, and\u002For there is midline shift, the patient will need to undergo treatment for these brain metastases and meet exclusion criteria #4 exception to treated brain metastases prior to enrollment. A new MRI brain is NOT required in this situation\n* Is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with informed consent through 180 days after the last dose of trial treatment\n* Has Child-Pugh class C cirrhosis from any cause\n* Mean triplicate screening electrocardiogram (EKG) corrected QT (QTc) \\> 480 ms. (QTc Framingham will be used for heart rate \\>100 bpm)\n* Grade 3 or 4 NYHA (New York Heart Association) congestive heart failure, unless screening echocardiogram obtained prior to enrollment showed a LVEF (left ventricular ejection fraction) ≥ 45%\n* Surgery within 4 weeks prior to first study dose\n* Requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A\n* Requires treatment with concomitant drugs that are strong inhibitors or inducers of P-glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the patient\n* Requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor, with the exception of drugs that are considered absolutely essential for the care of the patient\n* Active\u002Funtreated hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; patients with treated HBV and HCV are allowed as long as they meet the AST\u002FALT and bilirubin criteria\n* Known hypersensitivity to gilteritinib or any of the excipients\n* Active and clinically significant pancreatitis",{"count":166,"type":22},30,[168],"PHASE1","This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung cancer (NSCLC) who have progressed on other treatments. While there are many approved targeted drugs for ALK NSCLC, resistance to these drugs frequently occur. Giltertinib is a drug that is already FDA approved for the treatment of a specific type of leukemia. However, studies using ALK positive lung cancer cells demonstrate activity of gilteritinib against these resistant cells. Therefore, in this clinical trial, the investigators plan to study the effect of giltertinib in patients with ALK NSCLC.",[171,172],"Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8",{"date":152,"type":35},{"date":175,"type":35},"2024-07-25",{"date":177,"type":22},"2027-05",{"name":41,"class":42},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},"100489459","metastatic-leiomyosarcoma-biomarker-protocol-100489459","NCT05653388","Metastatic Leiomyosarcoma Biomarker Protocol","Observational Study of Biomarkers of Disease-related Outcomes in Patients With Metastatic Leiomyosarcoma Receiving Chemotherapy","Inclusion Criteria:\n\n* Patients with unresectable or metastatic leiomyosarcoma (LMS). There is no age requirement\n* Receiving first-line chemotherapy with doxorubicin- based or gemcitabine\u002Fdocetaxel\n* Target lesions per RECIST 1.1\n* Optional archival tumor tissue including 1 H\\&E-stained slide and unstained tumor tissue \\[either tissue block containing tumor, or minimum of 4 unstained slides (preferably 8 unstained slides)-fresh frozen sample may also be used in lieu of FFPE sample\\] available for study research",{"count":187,"type":22},200,"Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of metastatic disease. A minority of patients benefit from treatment with chemotherapy and early biomarkers of benefit from treatment are lacking. A biomarker of tumor response and patient survival benefit from chemotherapy early in the course of chemotherapy would be of significant impact in treatment planning. Circulating tumor DNA (ctDNA) is present in blood of patients with advanced\u002Fmetastatic cancer and may serve as biomarker of tumor response to chemotherapy. Blood samples will be collected prior to and during and chemotherapy, and analyzed for ctDNA and for mutations in genes that are associated with increased risk of developing sarcoma. Tumor tissue will be collected and analyzed for changes in genes. Digital images of the sarcoma from CT or MRI scans obtained during treatment will be obtained for advanced radiomic analysis. Study participants will be asked to complete a questionnaire on attitudes and understanding of genetics and genetic testing.",[84],[86,191,87],"Biomarker",{"date":100,"type":35},{"date":194,"type":35},"2022-12-22",{"date":196,"type":22},"2026-12",{"name":41,"class":42},11,{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":43},"100621006","a-virtually-delivered-diet-intervention-laso-3-for-the-improvement-of-chemotherapy-induced-peripheral-neuropathy-in-cancer-survivors-post-treatment-100621006","NCT07365007","A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment","Feasibility of a Virtually Delivered LASO-3 Diet Intervention for Chemotherapy-Induced Peripheral Neuropathy in Post-Treatment Cancer Survivors","Inclusion Criteria:\n\n* 18 years or older\n* At least three months since last receiving neurotoxic chemotherapy\n* Self-report moderate (≥ 2\u002F4) numbness and tingling on the Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE™) Numbness and Tingling Severity Item in the last week\n* Speak\u002Fread English\n* Have access to the internet\n\nExclusion Criteria:\n\n* Pre-existing peripheral neuropathy from any cause\n* Plan to begin a new prescription of duloxetine (i.e., first-line treatment for CIPN pain) during the study period\n* Are enrolled in symptom management trials that may alter CIPN severity\n* High grade inflammatory disease such as lupus, Crohn's disease, or rheumatoid arthritis\n* Routine nonsteroidal anti-inflammatory drug (NSAID) or steroid supplementation\n* Consuming an average three or more servings of fish per week and\u002For consuming fish oil capsules containing eicosapentaenoic acid (EPA)+ docosahexaenoic acid (DHA) daily or consuming flax oil capsules daily\n* Consuming an average of less than 5 servings of sweets, candy bars, chocolate, doughnuts, cookies, cakes, pie, brownies, ice cream, pastries, or sugar sweetened beverages (e.g., soda or coffee\u002Ftea) per week",{"count":21,"type":22},[25],"This clinical trial studies whether a virtually delivered diet intervention focused on lower added sugar, higher fiber, and higher omega 3 fatty acid (LASO-3) can be used to improve chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors after treatment. Cancer survivors often experience CIPN during and after cancer treatment with neurotoxic chemotherapy. CIPN is characterized by nerve damage from chemotherapy that leads to numbness, tingling, or pain in the hands or feet. However, there are few treatments to manage CIPN. Inflammation contributes to the development of CIPN and dietary patterns that have been demonstrated to improve diet quality and reduce inflammation in cancer survivors may be promising for use as a CIPN management strategy. The LASO-3 diet intervention consists of virtually delivered nutrition education sessions provided by a Registered Dietitian. The sessions focus on three dietary goals, informed by the United States Dietary Guidelines for Americans: 1) lowering added sugar intake to \\\u003C 10% of daily calories, 2) increasing daily fiber intake to ≥ 20 grams, and 3) increasing intake of moderate-high omega-3 seafood to three or more servings weekly or 3300-3400 mg\u002Fday of alpha-linolenic acid (e.g., plant-based sources include canola or flaxseed oil, walnuts, or flaxseed or chia seeds). The Registered Dietitian tailors the sessions to the patient based on information and feedback obtained throughout the sessions. The LASO-3 diet intervention may be an effective way to improve CIPN in cancer survivors after treatment.",[28,29,30],"2026-06-22",{"date":212,"type":35},"2026-06-25",{"date":214,"type":35},"2026-02-23",{"date":216,"type":22},"2028-03-01",{"name":41,"class":42},{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":241},"100543460","phase-2-study-of-neoadjuvant-enfortumab-vedotin-and-pembrolizumab-in-cisplatin-eligible-upper-tract-urothelial-cancer-100543460","NCT06356155","Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer","A Phase II, Open-label, Single-arm, Multi-center Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer (NEPTUNE)","NEPTUNE","Inclusion Criteria:\n\n* Patients must have a diagnosis of high-grade upper tract (renal pelvis and\u002For ureter) urothelial carcinoma proven by biopsy or cytology within 60 days prior to registration with the following (cT1-4 N0-1 M0): a. Upper urinary tract mass on cross-sectional imaging or Tumor directly visualized during upper urinary tract endoscopy before referral to medical oncology. b. No regional lymph node metastasis or a single regional lymph node metastasis.\n* Patients must not have any component of small cell carcinoma. Other variant histologic types are permitted provided the predominant (≥50%) subtype is urothelial carcinoma.\n* Patients must be considered to be a candidate for definitive surgery (nephroureterectomy or distal ureterectomy) with curative intent by the treating urologist. Lymph node dissection is strongly encouraged but its scope and determination will be at the discretion of the treating urologist. Details of the surgery such as bladder cuff removal are left to the discretion of the treating urologist. Robotic or open approaches are allowed.\n* Patients must be eligible for cisplatin. Cisplatin eligibility is defined as meeting all of the following criteria: a. Creatinine clearance ≥ 45 mL\u002Fmin calculated by Cockcroft-Gault equation (using actual body weight) or measured by 24-hour urine collection. b. Absence of Grade ≥ 2 peripheral neuropathy. c. Absence of New York Heart Association Class III or higher heart failure.\n* Prior local endoscopic therapy for upper tract urothelial cancer is permitted if completed at least 6 months prior to the initiation of study treatment and if all toxicities from such therapy have improved to grade 1 or resolved.\n* Prior uro-oncologic history: a. History of or active non-invasive carcinoma or carcinoma in situ of the bladder\u002Furethra or upper tract is allowed. b. Patients may have received prior intravesical chemotherapy or immunotherapy such as BCG. c. Prior neoadjuvant or adjuvant chemotherapy or antibody-drug conjugate for bladder cancer or invasive contralateral upper tract cancer is allowed but must have been completed ≥ 1 year prior to study registration.\n* Patients must be age ≥ 18 on the date of registration.\n* ECOG Performance Status 0-1.\n* Criteria for patients with hepatitis B or C are listed below. Hepatitis B and C screening tests are not required unless there is a known history of HBV or HCV infection or as mandated by local healthy authority. Hepatitis B positive subjects • Participants who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to enrollment. • Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention. Participants with history of HCV infection are eligible if HCV viral load is undetectable at screening. • Participants must have completed curative anti-viral therapy at least 4 weeks prior to enrollment.\n* Patients must have adequate organ and bone marrow function as defined in Table 1. Specimens must be collected within 14 business days prior to start of study enrollment.\n* Women and men of reproductive potential must agree to use an effective contraceptive method during treatment and for 4 months after the last dose of study drug. See Section 16.3, Appendix 3. Men must also refrain from donating sperm during this period.\n* Women of reproductive potential must have a negative pregnancy test within 14 days prior to registration and are not breastfeeding.\n* Patients must not have any other medical condition(s) that make(s) their participation in the study unadvisable in the opinion of the treating oncologist.\n* All patients must be informed of the investigational nature of this study. The patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity who have a legally authorized representative or caregiver and\u002For family member available will also be considered eligible.\n\nExclusion Criteria:\n\n* Prior exposure to immune-mediated therapy, including but not limited to, other anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4), anti-PD1, anti-PD-L1, anti-PD-L2 antibodies, and therapeutic anticancer vaccines.\n* Prior exposure to monomethyl auristatin E antibody-drug conjugates (MMAE ADC).\n* Patient is currently on or used immunosuppressive medication within 14 days prior to the first dose of pembrolizumab. The following are exceptions to this criterion: o Intranasal, inhaled, intra-auricular, topical steroids, or local steroid injections (e.g., intra-articular injection). o Use of chronic immunosuppressive agents at baseline at doses not to exceed more than prednisone 10 mg\u002Fday or equivalent. o Steroids as premedications for hypersensitivity reactions (e.g., CT scan premedication).\n* Active or prior documented autoimmune or inflammatory disorders requiring immunosuppressive therapy within 2 years prior to registration. Exceptions are well-controlled hyper\u002Fhypothyroidism, celiac disease controlled by diet alone, diabetes mellitus type 1, alopecia, psoriasis, eczema, lichen planus, vitiligo, or similar skin\u002Fmucosa conditions.\n* Evidence of metastasis (N2-3 or M1) on axial imaging at baseline.\n* History of invasive, node positive, or metastatic bladder cancer OR invasive contralateral upper tract cancer within 2 years prior to registration.\n* Enrolled in another interventional clinical trial at the time of registration.\n* Patient has another active malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 1 year. The time requirement does not apply to participants who underwent successful definitive resection of non-melanoma skin cancers, superficial bladder cancer (described above in inclusion criteria 6), in situ cervical cancer, other in situ cancers, or either clinically insignificant per the investigator (e.g., ≤Gleason 3+4) on surveillance or previously treated prostate cancer without rising PSA and no plan to treat. NOTE: Patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patient has one kidney.\n* Patient is pregnant or lactating.\n* Has severe hypersensitivity (≥ Grade 3) to enfortumab vedotin, pembrolizumab, and\u002For any of its excipients.\n* Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines are live attenuated vaccines and are not allowed.\n* Has an active infection requiring systemic therapy.\n* Has a history or current evidence of any condition or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has a known history of Human Immunodeficiency Virus (HIV) infection.\n* Has a known history of active TB (Bacillus Tuberculosis).\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Has had an allogenic tissue (e.g., hematopoietic stem cell transplant HSCT)\u002Fsolid organ transplant.\n* Has ongoing clinically significant toxicity (Grade 2 or higher with the exception of alopecia) associated with prior treatment.\n* Has known active keratitis or corneal ulcerations\n* Has any of the following: a. Moderate or severe liver dysfunction (does not meet hepatic function laboratory criteria outlined in Table 1). b. Uncontrolled diabetes mellitus as deemed by Hemoglobin A1c of 8 or greater.",{"count":227,"type":22},32,[143],"This trial is a multi-site, single-arm, phase 2 trial of neoadjuvant combination of enfortumab vedotin and pembrolizumab in cisplatin-eligible patients with high-grade localized\u002Flocally advanced cT1-4 N0-1 M0 upper tract urothelial cancer who are deemed eligible for curative-intent surgery (radical nephroureterectomy or distal ureterectomy) followed by adjuvant pembrolizumab.",[231],"Urothelial Carcinoma",[233,234],"Neoadjuvant","cisplatin-eligible",{"date":125,"type":35},{"date":237,"type":35},"2025-07-22",{"date":239,"type":22},"2028-03",{"name":41,"class":42},2,{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":43},"100605092","phase-2-leuprolide-and-goserelin-for-ovarian-function-suppression-in-pre--or-peri-menopausal-women-with-breast-cancer-ofs-trial-100605092","NCT07158021","Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial","Phase 2 Interventional Trial of Ovarian Function Suppression for Breast Cancer (OFS)","Inclusion Criteria:\n\n* Female subject aged ≥ 18 years\n* Pre- or peri-menopausal patient, who had (1) menses either within the 12 months prior to or since breast cancer diagnosis or (2) estradiol concentration above the postmenopausal range per institutional laboratory guidance either within the 12 months prior to or since breast cancer diagnosis.\n* Planning to take GnRHa therapy in combination with oral endocrine therapy (tamoxifen, anastrozole, exemestane, or letrozole) for adjuvant treatment of stage 1-3 breast cancer or for treatment of metastatic breast cancer. Prior treatment with GnRHa therapy for treatment of non-oncologic conditions or during chemotherapy is permitted.\n* Not planning bilateral salpingo-oophorectomy during the 6-month study duration\n* Completion of chemotherapy, if given. Concurrent use of trastuzumab, pertuzumab, bisphosphonate therapy, poly adenosine diphosphate-ribose polymerase (PARP) inhibitor therapy, cyclin D kinase 4\u002F6 (CDK4\u002F6) inhibitor, and\u002For phosphoinositide 3-kinase (PI3K) inhibitor therapy is permitted\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines\n\nExclusion Criteria:\n\n* Prior bilateral salpingo-oophorectomy\n* Known to be pregnant or breastfeeding (negative pregnancy test will be confirmed prior to study treatment initiation)\n* Concomitant use of systemic or transdermal estrogen products\n* Known allergy or hypersensitivity to goserelin or leuprolide, or any of the excipients in the medications\n* Unable to take oral medications\n* Any medical condition that would interfere with the absorption of endocrine therapy. Prior gastric bypass is permitted\n* Patients with a prior or concurrent malignancy whose natural history or treatment, in the opinion of the treating investigator, has the potential to interfere with the safety or efficacy assessment of the investigational regimen",{"count":250,"type":22},75,[143],"This phase II trial compares leuprolide to goserelin for reducing estrogen production by the ovaries in pre- or peri-menopausal women with breast cancer. Estrogen can cause the growth of breast cancer cells. Both leuprolide and goserelin lower the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. This study compares lower dose leuprolide, higher dose leuprolide, and goserelin for their ability to suppress the function of the ovaries to produce estrogen. Both doses of leuprolide may be as safe, tolerable and\u002For effective as goserelin in suppressing ovarian function in pre- or peri-menopausal women with breast cancer.",[254,255,256,257,258],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","2026-06-18",{"date":125,"type":35},{"date":262,"type":35},"2026-01-22",{"date":264,"type":22},"2028-01-01",{"name":41,"class":42},{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":273,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":43},"100587404","navigation-interventions-to-improve-cascade-genetic-testing-among-relatives-of-patients-with-hereditary-cancer-syndromes-100587404","NCT06927947","Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes","Testing Effectiveness of Navigation Interventions to Increase Uptake of Cascade Genetic Testing Among Relatives of Individuals Diagnosed With Hereditary Cancer Syndromes","Inclusion Criteria:\n\n* PROBANDS: Clinically confirmed autosomal dominant pathogenic germline variant (PGV) associated with a hereditary cancer syndrome\n* PROBANDS: Previous evaluation by the University of Michigan (U-M) Cancer Genetics Clinic\n* PROBANDS: ≥ 18 years old\n* PROBANDS: Able to speak and read English\n* PROBANDS: Access to the internet\n* RELATIVES: Biological relative of proband\n* RELATIVES: ≥ 18 years old\n* RELATIVES: Able to speak and read English\n* RELATIVES: Access to the internet\n* RELATIVES: Have not completed germline genetic testing, per self-report at baseline\n\nExclusion Criteria:\n\n* RELATIVES: Prior clinical germline genetic testing for cancer or already have an upcoming appointment scheduled with a genetics provider, per self-report at baseline",true,{"count":275,"type":22},625,[25],"This clinical trial tests whether various web-based tools can help improve communication about hereditary cancer risk in families and decrease barriers to genetic testing for relatives of patients with hereditary cancer syndromes. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or certain cancers diagnosed in biological relatives may mean patients are more likely to have a genetic change. Once a genetic change is identified in a family, other biological relatives can choose to undergo testing themselves to better understand their cancer risk. The uptake of genetic testing in other biological relatives once a genetic condition is identified is about 20% to 30%. The Cascade Genetic Testing Platform is a virtual tool that seeks to overcome barriers related to logistics of family communication and improve dissemination of genetic testing information which is clinically actionable for individuals at highest risk for cancer. Using the Cascade Genetic Testing Platform may improve ways to share information about hereditary risk with biological relatives.",[279,280],"Hereditary Malignant Neoplasm","Hereditary Neoplastic Syndrome","2026-06-11",{"date":283,"type":35},"2026-06-15",{"date":285,"type":35},"2025-09-23",{"date":287,"type":22},"2026-09-30",{"name":41,"class":42},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":17,"minAge":296,"maxAge":114,"enrollmentInfo":297,"targetDuration":4,"studyType":23,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":304,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":43},"100586369","phase-1-virus-based-gene-therapy-adv-hsv1-tk-and-adv-flt3l-in-combination-with-valacyclovir-for-the-treatment-of-pediatric-and-young-adult-patients-with-resectable-recurrent-primary-malignant-brain-tumors-100586369","NCT06914479","Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors","A Phase 1 Study of a Combined Cytotoxic and Immune-Stimulatory Therapy in Pediatric and Young Adult Patients With Recurrent, Primary Malignant Brain Tumors","Inclusion Criteria:\n\n* Age 3 to 25 years with:\n\n  * Diagnosis of malignant primary brain tumor after tumor recurrence, relapse, or progression who have completed up-front, standard-of-care therapy\n* Age 26 to 39 years with:\n\n  * Diagnosis of diffuse hemispheric glioma, H3 G34-mutant, per 2021 World Health Organization (WHO) classification, after tumor recurrence, relapse, or progression who have completed up-front, standard-of-care therapy\n* At least 10 kg (and body surface area \\[BSA\\] \\> 0.5 m\\^2)\n* Participants who are receiving corticosteroids must be on a stable or decreasing dose for at least 3 days prior to baseline MRI\n* Surgical resection of the tumor recurrence\u002Frelapse\u002Fprogression is clinically indicated at the time of enrollment\n* A legal parent\u002Fguardian or patient must be able to understand, and willing to sign, a written informed consent and assent document, as appropriate\n* Participant must be willing to provide archival formalin-fixed embedded (FFPE) and\u002For frozen tissue specimens, if available\n* Participant must have recovered from all acute side effects of prior therapy.\n\n  * From the projected start of scheduled study treatment, the following time periods must have elapsed: At least 7 days after last dose of a biologic agent or beyond time during which adverse events are known to occur for a biologic agent, 5 half-lives from any investigational agent, 4 weeks from cytotoxic therapy (except 23 days for temozolomide and 6 weeks from nitrosoureas), 6 weeks from antibody therapy (21 days for bevacizumab,.6 weeks from cellular therapy (i.e. modified T cells, natural killer \\[NK\\] cells, dendritic cells, etc.), or 4 weeks (or 5 half-lives, whichever is shorter) from other antitumor therapies\n* For participants who have received radiotherapy previously, participants must be at least 28 days from focal radiation therapy, at least 150 days from craniospinal irradiation therapy.\n\n  * The use of bevacizumab to control radiation therapy-induced edema is allowed prior to or during study therapy (if used for tumor-directed therapy, please see required washout period above).\n\n    * Dosing limitations are as follows:\n\n      * Bevacizumab (or bioequivalent) for up to a maximum of 5 doses, dosing per institutional standard. There is no required washout period\n* Prior use of temozolomide during radiation at maximum of the standard pediatric dosing (defined as 90 mg\u002Fm\\^2\u002Fdose continuously during radiation therapy) or dexamethasone is allowed\n* Peripheral absolute neutrophil count (ANC) ≥ 1000\u002Fmm\\^3 (1.0g\u002Fl)\n* Platelet count ≥ 100,000\u002Fmm\\^3 (100x10\\^9\u002Fl) (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\n* Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 70mL\u002Fmin\u002F1.73 m\\^2 or a serum creatinine within the normal limits for age\n* Bilirubin (sum of conjugated + unconjugated) ≤ 2 x upper limit of normal (ULN) for age\n* Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 3 x ULN\n* Serum albumin ≥ 2 g\u002FdL\n* Performance score ≥ 60 (Karnofsky for participants \\> 16 years of age, Lansky for participants ≤ 16 years of age.)\n\n  * Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score\n* The effects of the study drugs on the developing human fetus are unknown. For this reason, females of child-bearing potential (FOCBP) and males must agree to use adequate contraception for the duration of study participation and 30 days after last dose of AdV-HSV1-TK\u002FAdV-Flt3L or valacyclovir, whichever is later.\n\n  * Adequate methods include hormonal or barrier method of birth control, or abstinence at the time of study entry and for the duration of study participation.\n  * Should a participant become pregnant or suspects she is pregnant while participating in this study, she should inform her treating physician immediately.\n  * Males treated on this study must also agree to use adequate contraception as of the time of enrollment onto the study and for the duration of study participation. Male participants must notify the treating physician immediately if his partner becomes pregnant while he is receiving study therapy\n\nExclusion Criteria:\n\n* Patient deemed not clinically appropriate to undergo tumor tissue resection by a neurosurgeon\n* Evidence of disseminated disease, including diffuse leptomeningeal disease or evidence of cerebrospinal fluid (CSF) dissemination\n* Patient with primary brainstem or primary spinal tumors\n* History of prior gene therapy\n* Ongoing therapy with valacyclovir that is unable to be stopped due to a medical condition\n* Known allergy to valacyclovir\n* Concurrent use of other investigational agents.\n\n  * Participants who are currently receiving another investigational drug. Investigational imaging agents or agents used to enhance tumor visibility on imaging or during tumor biopsy\u002Fresection should be discussed with the study chairs\n* Participants who are currently receiving anti-cancer agents\n* Participants with a known disorder that affects their immune system, such as HIV or hepatitis B or C, or an auto-immune disorder requiring systemic cytotoxic or immunosuppressive therapy\n* Presence of uncontrolled infection or other uncontrolled systemic illness\n* Current diagnosis of bipolar disorder or major depressive disorder\n* Presence of a congenital immune deficiency syndrome or acquired autoimmune disease\n* Female participants of childbearing potential must not be pregnant or breast-feeding. Female participants of childbearing potential must have a negative serum or urine or serum pregnancy test prior to the start of therapy (as clinically indicated)\n* Active illicit drug use or diagnosis of alcoholism\n* History of kidney transplant\n* History of allogeneic stem cell transplantation\n* Known additional malignancy that is progressing or requires active treatment within 3 years of start of study drug","3 Years",{"count":198,"type":22},[168],"This phase I trial tests the safety, side effects and best dose of AdV-HSV1-TK and AdV-Flt3L in combination with valacyclovir for the treatment of patients with primary cancerous (malignant) brain tumors that can be removed by surgery (resectable) and that have come back after a period of improvement (recurrent). AdV-HSV1-TK and AdV-Flt3L use a virus modified in the laboratory to kill tumor cells and stimulate the immune system to recognize the tumor cells as \"invaders\" which can lead to tumor shrinkage. For this process to work, an oral anti-herpes medication called valacyclovir is also needed. Giving AdV-HSV1-TK, AdV-Flt3L and valacyclovir may be safe, tolerable and\u002For effective in treating patients with resectable, recurrent primary malignant brain tumors.",[301,302,303],"Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant","Recurrent Malignant Brain Neoplasm","Resectable Brain Neoplasm",{"date":283,"type":35},{"date":306,"type":35},"2026-05-22",{"date":308,"type":22},"2031-05",{"name":41,"class":42},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":316,"minAge":317,"maxAge":318,"enrollmentInfo":319,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":43},"100643062","targeted-early-detection-program-in-men-at-high-genetic-risk-for-prostate-cancer-100643062","NCT07645391","Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer","Inclusion Criteria:\n\n* \\* Age 35-70 years\n\n  * Capable of providing informed consent\n  * Prognosis of \\> 5 years if affected by another cancer\n  * Patients need one to meet at least one of the following high genetic risk categories:\n\n    * Known PCa-related mutations: BRCA 1 and 2, Lynch syndrome, or p53\n    * Carrier of mutation in a suspected PCa-related gene: e.g., ATM, PALB2, CHEK2, RAD51D, ATR, NBN, GEN1, RAD51C, MRE11A, BRIP1, FAM175A, HOXB13\n    * Obligate carriers of the above mutations (e.g. their sisters\u002Fdaughters have known mutations)\n    * Men with any family history of above mutation\n    * Family history of breast, prostate, or ovarian cancer in at least 2 individuals, or in 1 individual diagnosed before age 50\n\nExclusion Criteria:\n\n* \\* Anuria\n\n  * Prior diagnosis or treatment for PCa\n  * Failure to provide informed consent\n  * Life expectancy \\\u003C 5 years","MALE","35 Years","70 Years",{"count":187,"type":22},"This study evaluates urinary biomarkers and PSA to help determine the best approach to early detection of prostate cancer in patients with an elevated familial risk.",[322],"Prostate Carcinoma","2026-06-08",{"date":325,"type":35},"2026-06-12",{"date":327,"type":35},"2017-01-01",{"date":329,"type":22},"2030-01",{"name":41,"class":42},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":23,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":350,"leadSponsor":352,"locationsCount":43},"100633887","phase-1-pomalidomide-after-car-t-cell-therapy-for-the-treatment-of-relapsed-or-refractory-cd19-b-cell-leukemia-or-lymphoma-100633887","NCT07532525","Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma","A Single-Center, Single-Arm, Phase 1 Pilot Study of Pomalidomide Following CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed\u002FRefractory CD19+ B-Cell Leukemias and Lymphomas","Inclusion Criteria:\n\n* Subject must have had a histologically or cytologically confirmed R\u002FR CD19+ B-cell leukemia or lymphoma and have received a commercially available CAR-T product approved to treat R\u002FR CD19+ Bcell leukemias and lymphomas.\n* Subject must be 28 - 56 days post infusion of CD19CART product at time of enrollment.\n* \\>= 18 years in age at time of enrollment\n* Subject is able to swallow pills\u002Ftablets\n* Karnofsky or Lansky performance score of \\>= 50%\n* Absolute neutrophil count (ANC) \\>= 750\u002Fmm\\^3 (granulocyte colony stimulating factor allowed)\n* Platelets \\>= 50,000\u002Fmm\\^3 (transfusion independent for \\>= 7 days, defined as not receiving platelet transfusions for at least 7 days prior to enrollment, unless due to marrow involvement from primary malignancy \\[thrombopoietin (TPO) mimetics allowed\\])\n* Total bilirubin =\\\u003C 1.5 x upper limit of normal (ULN) per institution\n* Alanine aminotransferase (ALT \\[serum glutamate pyruvate transaminase (SGPT)\\]) =\\\u003C 3 x institutional ULN per institution\n* Serum albumin \\>= 2.0 g\u002FdL\n* Creatinine clearance (Cockcroft-Gault equation) \\>= 30 mL\u002Fmin\u002F1.73 m\\^2\n* Sexually active females capable of becoming pregnant and males must agree to participate in the pomalidomide Risk Evaluation and Mitigation Strategy (REMS) program\n* Patients must agree not to donate blood during treatment with pomalidomide and for 4 weeks following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed to pomalidomide\n\nExclusion Criteria:\n\n* Patients with known progressive or refractory disease.\n* The following transplant or CAR T-related events are excluded:\n\n  * Active grade \\>= 2 acute or chronic graft versus host disease (GVHD)\n  * Active cytokine release syndrome (CRS) grade \\>= 2\n  * Active immune effector cell associated neurotoxicity (ICANS) grade \\>= 2\n* Subject receiving \\>= 0.25 mg\u002Fkg\u002Fday of methylprednisolone equivalent. Subject being treated with medications with a known major drug interaction to pomalidomide. Specifically, patients receiving CYP1A2 inhibitors, such as ciprofloxacin, omeprazole, cimetidine, estrogen, and fluvoxamine.\n* Patient who smokes cigarettes.\n* Subject must not have initiated or received intervening therapy for a primary or secondary malignancy within 28 days of study enrollment, including, a) myelosuppressive chemotherapy, b) biologic anti-neoplastic agents (e.g., ruxolitinib, imatinib, dasatinib…), or checkpoint inhibitors (e.g., pembrolizumab). The use of cytokine inhibition for management of CRS\u002FICANS is allowed within the prior 28 days\n* Receipt of radiation therapy (XRT) (focal or large field, including cranial or cranial-spinal) within 28 days prior to enrollment\n* Stem cell transplant or rescue following most recent CD19CART therapy\n* History of allergic reactions to pomalidomide or any of the excipients and any similar compounds\n* Intercurrent illness or conditions:\n\n  * Patients with uncontrolled infections. In addition, patients with any documented bacteremia, fungemia, or new onset viremia that requires antimicrobial therapy within 72 hours prior to enrollment. Empiric antimicrobials are allowed\n  * Active grade \\>= 4 gastrointestinal, hepatic, pulmonary, renal, cardiac toxicity by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 criteria. Patients requiring dialysis are excluded\n  * Patients with concomitant genetic syndromes associated with bone marrow failure states: such as patients with Fanconi anemia, severe congenital neutropenia, Schwachman syndrome or any other known bone marrow failure syndrome. Patients with Down syndrome are not excluded\n  * History of known prior arterial thromboembolism, venous thromboembolism, pulmonary embolism, cardiovascular accidents, or myocardial infarctions within 3 months prior to enrollment\n* Pregnant women are excluded from this study. Women should discontinue breastfeeding during treatment and for at least 4 weeks after discontinuation of study drug\n* HIV positivity within 8 weeks of screening on polymerase chain reaction (PCR) based assay",{"count":339,"type":22},12,[168],"This phase I trial tests the safety and effectiveness of pomalidomide after CD19 chimeric antigen receptor T-cell (CD19CART) therapy for the treatment of patients with CD19+ B-cell leukemias or lymphomas that have come back after a period of improvement (relapsed) or do not respond to treatment (refractory). Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T-cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells and are then re-infused into the patient. Following CAR T-cell infusion, CAR T-cells must expand and persist in the blood stream in order to most effectively treat leukemia\u002Flymphoma. Pomalidomide stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Research has shown that drugs like pomalidomide can modify the immune system and increase the number or improve the function of CAR T-cells in the blood. Pomalidomide may enhance the treatment effects of CAR T-cell therapy in patients who have received CD19CART therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma.",[343,344,345,346],"Recurrent B Acute Lymphoblastic Leukemia","Recurrent B-Cell Non-Hodgkin Lymphoma","Refractory B Acute Lymphoblastic Leukemia","Refractory B-Cell Non-Hodgkin Lymphoma",{"date":348,"type":35},"2026-06-09",{"date":64,"type":22},{"date":351,"type":22},"2028-08",{"name":41,"class":42},{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":273,"sex":316,"minAge":361,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":23,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":43},"100633427","urine-prostate-screening-integrated-with-mri-for-early-detection-of-prostate-cancer-uprise-trial-100633427","NCT07526545","Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial","UPRISE (Urine Prostate Screening Integrated With MRI for Prostate Cancer Early Detection)","UPRISE","Inclusion Criteria:\n\n* Males aged 50-75\n* PSA 3-20 ng\u002Fml within the previous 3 months\n* Fit to undergo all procedures listed in protocol per treating physician's discretion\n* No prostate biopsy in the past 4 years\n* No prostate MRI in the past 2 years\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Prior diagnosis of prostate cancer\n* Contraindication to MRI (e.g. claustrophobia, pacemaker)\n* Contraindication to prostate biopsy\n* Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work","50 Years","75 Years",{"count":364,"type":22},800,[25],"This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.",[322],{"date":348,"type":35},{"date":370,"type":22},"2026-09-01",{"date":372,"type":22},"2030-03-01",{"name":41,"class":42},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":23,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":43},"100639280","office-based-ureteroscopy-utilizing-a-single-use-digital-flexible-ureteroscope-for-upper-tract-urothelial-carcinoma-100639280","NCT07630155","Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma","A Prospective Clinical Assessment of Office-Based Ureteroscopy for Upper Tract Urothelial Carcinoma Utilizing a 6.3 French Single Use Digital Flexible Ureteroscope","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged ≥ 18 year. Both sexes are included to reflect the patient population with upper tract urothelial carcinoma (UTUC) already being followed at the University of Michigan and allow exploration of potential differences in tolerability of awake ureteroscopy based on sex\n* History of endoscopically managed UTUC at any time, or a suspected diagnosis of UTUC based on pre-procedure imaging, and is already planned for office-based ureteroscopic assessment\n* Ability and willingness to complete and adhere to survey questions and responses throughout study duration\n\nExclusion Criteria:\n\n* Known ureteral strictures\n* Active urinary tract infection\n* Need for general anesthesia due to patient or procedural factors\n* History of inability to tolerate ureteroscopy under local anesthetic\n* Anticipated need for laser ablation during the surveillance procedure\n* Pregnancy",{"count":382,"type":22},10,[25],"This clinical trial tests how well office based ureteroscopy utilizing a single use digital, flexible ureteroscope works for the assessment of upper tract urothelial carcinoma. Ureteroscopy is a procedure in which a thin camera called a ureteroscope is used to assess patients with a known or suspected diagnosis of upper tract urothelial carcinoma. Ureteroscopy is traditionally performed in an operating room under general anesthesia. In this study, patients undergo ureteroscopy in the doctor's office using an ultra-thin ureteroscope, which is the narrowest instrument of its kind. Because of its small size, researchers believe this procedure can be completed in the office with minimal discomfort and high patient satisfaction, which may eliminate the risks of general anesthesia and reduce delays to diagnosis. Office based ureteroscopy utilizing a single use digital, flexible ureteroscope may be effective for the assessment of upper tract urothelial carcinoma.",[386],"Renal Pelvis and Ureter Urothelial Carcinoma","2026-06-01",{"date":389,"type":35},"2026-06-05",{"date":391,"type":22},"2026-07-18",{"date":393,"type":22},"2027-07",{"name":41,"class":42},{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":273,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":23,"phases":404,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":414,"leadSponsor":416,"locationsCount":43},"100634647","a-web-based-program-kindred-to-improve-the-understanding-of-genetic-cancer-risk-and-cancer-genetic-testing-in-african-american-families-100634647","NCT07542405","A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families","Kindred: Family Centered Approaches to Promoting Cascade Screening for Hereditary Cancer Syndromes Among African Americans","Inclusion Criteria:\n\n* PROBANDS: Evaluation in the past one-year at the Breast and Ovarian Cancer Risk Evaluation Clinic (BOCRE) or Cancer Genetics Clinic, both located at the University of Michigan (U-M) Rogel Cancer Center who are positive for hereditary breast and ovarian cancer syndrome (HBOC) (BRCA1, BRCA2) or Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM); indeterminate negative; or variants of uncertain clinical significance (VUS). If more than one biological relative is known to have received an evaluation for and or completed germline testing for cancer risk, the relative who was evaluated the longest time ago to align with the tradition definition of a proband as defined by the National Cancer Institute (NCI), i.e., the first person identified as possibility having a genetic disorder and who may receive counseling or testing\n* PROBANDS: \\>= 18-years-old\n* PROBANDS: Completed genetic testing for hereditary cancer syndromes, regardless of results\n* PROBANDS: Able to speak and read English\n* PROBANDS: Access to the internet\n* PROBANDS: Identifies as African American or Black (may have additional race or ethnicity identities)\n* RELATIVES: Biological relative of enrolled proband, regardless of testing completion or timing of testing\n* RELATIVES: \\>= 18 years old\n* RELATIVES: Able to speak and read English\n* RELATIVES: Access to the internet\n\nExclusion Criteria:\n\n* PROBANDS: No evaluation at U-M or other facility, or evaluation was more than one year ago, or received an evaluation more recently than the relative\n* PROBANDS: Under 18-years-old\n* PROBANDS: Did not receive cancer genetic testing\n* PROBANDS: Does not speak or read English\n* PROBANDS: Does not have internet access\n* PROBANDS: Does not identify as African American or Black\n* RELATIVES: Not a biological relative of proband\n* RELATIVES: Under 18-years-old\n* RELATIVES: Does not speak or read English\n* RELATIVES: Does not have internet access",{"count":403,"type":22},150,[25],"This clinical trial studies whether a web-based program, Kindred, works to improve the understanding of genetic cancer risk and cancer genetic testing in African American families. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or a family history of cancer means individuals are more likely to have a genetic change. If a genetic change is identified in a family, other relatives can choose to undergo hereditary cancer genetic testing to better understand their cancer risk. In families where a genetic change is not identified, or results are uncertain, relatives may also benefit from discussing their cancer risk with providers and, in some cases, getting hereditary cancer genetic testing themselves. Research has shown that African Americans are less likely than other racial groups to engage in cancer genetic testing. Kindred is an online tool that provides information so individuals can learn about their cancer genetic test results, how cancer genetic testing can help individuals and families understand their overall cancer risk (and strategies for reducing risk), and ways to talk with each other about cancer risk and health. This may be an effective way to improve the understanding of genetic cancer risk and cancer genetic testing in African American families.",[407,408,280,409],"BRCA1-Related Hereditary Breast and Ovarian Cancer Syndrome","BRCA2-Related Hereditary Breast and Ovarian Cancer Syndrome","Lynch Syndrome","2026-05-18",{"date":412,"type":35},"2026-05-19",{"date":283,"type":22},{"date":415,"type":22},"2028-06",{"name":41,"class":42},{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":23,"phases":425,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":241},"100565371","trial-of-exercise-therapy-in-familial-adenomatous-polyp-fap-100565371","NCT06641310","Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)","Phase 1a\u002Fb Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)","Inclusion Criteria:\n\n* Individuals with FAP as defined by:\n\n  * Genetic diagnosis: APC germline mutation (with or without FAP family history), OR\n  * Clinical diagnosis: FAP phenotype with a history of more than 50 colorectal adenomas\n* Have an intact rectum defined as status post colectomy and ileocolonic anastomosis for polyposis or pre-colectomy\n* ≥ 5 rectal polyps \\> 2 mm in size on baseline lower endoscopy\n* Participants must have no evidence of invasive cancer for 6 months prior to screening and must be at least 6 months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy or radiation)\n* No initiation of daily use of sulindac, celecoxib or other non-steroidal anti-inflammatory medications (NSAIDs) within 3 months of day 1 and no initiation \\> 25% of the time (\\> 8 days\u002Fmonth) for the duration of study participation\n* No initiation of semaglutide, liraglutide (glucagon-like peptide-1 receptor agonist \\[GLP-1 receptor agonist\\]), tirzepatide (glucose-dependent insulinotropic polypeptide \\[GIP\\]), orlistat (lipase inhibitor) or other weight loss medications, within 3 months of day 1 and during study participation\n* Adults ≥ 18 years of age\n* Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Participants on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible\n* Lower endoscopy, required for participation in the study, is contraindicated in pregnancy. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and until after the end of study endoscopy is completed. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform the study team immediately\n* Inactive defined as ≤ 60 minutes of moderate or strenuous exercise per week over the past month as assessed by the Godin Leisure Time Exercise Questionnaire\n* No self-reported contraindications to regular exercise as evaluated by the Physical Activity Readiness Questionnaire (PAR-Q+)\n* Sufficient space to house a treadmill in primary residence for the intervention period or access to an approved treadmill (as determined by study exercise physiologist) for the intervention period (e.g., participant may have access to a treadmill via an existing membership to a health club)\n* Ability for study team to deliver and install exercise equipment in primary residence\n\n  * Note: If participant will be using treadmill from another source approved by study exercise physiologist, this inclusion criteria is not applicable\n* Internet or Wi-Fi connection. For participants without internet or Wi-Fi, a pre-paid cellular iPad will be provided\n* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures\n* Physician approval\n* Ability to understand and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* History of total proctocolectomy\n* Histologically-confirmed high-grade dysplasia or cancer on biopsy at screening\n* History of pelvic radiation\n* Participants receiving any other investigational agents\n* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* History of severe, progressive, or uncontrolled renal, genitourinary, hepatic, hematologic, endocrine, cardiac, vascular, pulmonary, rheumatologic, neurologic, psychiatric, or metabolic disturbances, or signs and symptoms thereof\n* Pregnant women are excluded since endoscopy is not recommended while pregnant",{"count":227,"type":22},[25],"The purpose of this phase 1a\u002Fb trial is to find out what amount of exercise would be best to use for preventing recurrence of colorectal polyps. It involves following one of four different amounts of exercise regimens on a treadmill for 26 weeks. A treadmill will be placed in each study participant's home for the duration of the study. The exercise regimen will be personalized for each participant and monitored remotely by exercise personnel. The in-person study visits occur during the usual standard of care endoscopy exam and during a follow-up exam that is 26 weeks later. Small rectal tissue biopsies, about the size of a grain of rice, will be taken before and after 26 weeks of exercise. The study visits also involve questionnaires, a stool sample, and a blood sample. This study will inform the design of larger, future trials to investigate whether or not recurrence of polyps can be achieved with exercise.",[428],"Familial Adenomatous Polyposis",{"date":412,"type":35},{"date":431,"type":35},"2026-05-13",{"date":433,"type":22},"2028-05",{"name":41,"class":42},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":452,"locationsCount":453},"100121127","evaluation-of-stool-based-markers-for-the-early-detection-of-colorectal-cancers-and-adenomas-100121127","NCT00843375","Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas","Inclusion Criteria:\n\n* Willing to sign informed consent\n* Able to physically tolerate removal of up to 60 ml of blood\n* Adults at least 18 years old\n* Willing to collect 1-2 stool samples and prepare a Fecal Immunochemical Test (FIT)\n* Pregnant or nursing women who otherwise meet the eligibility criteria may participate\n* Subjects with one of the following:\n\n  * Colorectal adenocarcinoma-not treated and in colon at time of stool collection (CRC bin)\n  * Adenoma-pathologically confirmed adenoma present in colon at time of stool collection (Adenoma Bin)\n  * Higher Risk Non-neoplastic Bin\n\n    * Subjects with a personal history of adenomas (confirmed by pathology) with none present on qualifying colonoscopy\n    * Subjects with a personal history of CRC (longer than 3 years ago because of exclusion criteria of cancer within last 3 years) with none present at time of qualifying colonoscopy\n    * Any family history of CRC (1st degree relative)\n    * Current positive screening stool test for blood, for DNA or for both within 12 months with no follow-up intervention.\n  * Average Risk, Non-neoplastic Bin\n\n    * No history or current finding of any colorectal neoplasia including CRC, adenomas, sessile serrated adenomas and no family history of CRC.\n    * Subjects who had CRC that was successfully treated at least three years ago may be considered eligible for the adenoma bin if their polyps are adenomas and there is no evidence of CRC, or for the higher risk non-neoplastic bin as noted above.\n    * Subjects whose screening colonoscopy shows any of these types of polyps may be included in the non-neoplastic or the higher risk non-neoplastic bin if they meet the other criteria noted above.\n\n      * Hyperplastic polyps\n      * Benign mucosal polyps\n      * Polypoid granulation tissue\n      * Prolapsed mucosal polyps\n      * Inflammatory polyp\n      * Transitional mucosal polyp\n      * Lipoma\n      * Gangleoneuroma\n      * Neuroma\n      * Hamartomatous polyp\n\nExclusion Criteria:\n\n* Cancer patients who have had any surgery, radiation, or chemotherapy for their current colorectal cancer prior to collecting the baseline samples\n* History of or clinically active Inflammatory Bowel Disease\n* Known HNPCC or FAP\n* Inability to provide informed consent.\n* Other active malignancy within 3 years of enrollment except any of the following:\n\n  * Squamous cell carcinoma of the skin\n  * Basal cell carcinoma of the skin\n  * Carcinoma in situ of the cervix, Stages Ia or Ib invasive squamous cell carcinoma of the cervix treated by surgery only. (Excluded if had pelvic radiation)\n  * Stage Ia Grade 1 adenocarcinoma of the endometrium treated with surgery\n* Patients on active chemotherapy or radiation treatment for any purpose\n* Known HIV or chronic active viral hepatitis\n* Women who are pregnant\n* CT colonography (virtual colonoscopy) patients",{"count":442,"type":22},1200,"Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, and age, not all patients are able to be screened. Researchers are working on other options for early detection that are as accurate as colonoscopy.\n\nThe purpose of this study if to determine if stool or blood can be used to detect colon cancers as early or earlier than colonoscopy. The researchers plan to use these samples to learn about specific proteins (also known as biomarkers) that may indicate colon polyps, colon cancer or an increased risk of developing colon cancer. In order to learn more about preventing and detecting colon and rectal cancer, we are collecting samples from subjects with cancer, adenomas, and colonoscopies who may be at risk for polyps.",[445],"Colonic Neoplasms","2026-05-07",{"date":448,"type":35},"2026-05-11",{"date":450,"type":35},"2019-08-07",{"date":239,"type":22},{"name":41,"class":42},13,{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":23,"phases":463,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":43},"100512714","phase-2-pembrolizumab-and-mogamulizumab-in-advanced-stage-relapsedrefractory-cutaneous-t-cell-lymphomas-100512714","NCT05956041","Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed\u002FRefractory Cutaneous T-cell Lymphomas","A Phase II Study of Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed\u002FRefractory Cutaneous T-cell Lymphomas","Inclusion Criteria:\n\n* Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\n* Age ≥ 18 years at the time of consent.\n* ECOG Performance Status of ≤ 1 within 7 days prior to Cycle 1 Day 1 treatment.\n* Histological confirmation of cutaneous T-cell lymphoma (Mycosis Fungoides\u002FSezary Syndrome) with Stage IIB-IVB disease (TNMB Classification).\n* Measurable disease according to Modified Severity Weighted Assessment Tool (mSWAT) within 30 days prior to treatment.\n* Patients must have measurable, unirradiated disease. Prior disease radiation, if greater than 7 days prior to C1D1, is acceptable (see protocol). However, patient must have measurable disease that has not been radiated.\n* Patients must have failed at least one prior line of systemic therapy. This includes ECP. Prior cancer treatment must be completed at least 28 days prior to Cycle 1 Day 1(C1D1) and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤ grade 1 or baseline.\n* Archival tissue is required and will be identified at screening and shipped prior to C1D1 (10-15 unstained slides; obtained within 90 days of registration). Subjects that do not have archival tissue will be required to undergo a skin biopsy.\n* Systemic steroids at a dose less than the equivalent of 10 mg\u002Fday of prednisone and inhaled, nasal, and topical steroids are permitted. Adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent in the absence of active autoimmune disease are permitted. Treatment with a short course of steroids (\\\u003C 5 days) up to 7 days prior to study registration is permitted.\n* Demonstrate adequate organ function as defined below. All screening labs to be obtained within 28 days prior to Cycle 1 Day 1.\n\n  * Hematological\n  * Absolute Neutrophil Count (ANC) ≥ 500\u002FµL\n  * Hemoglobin (Hgb) ≥ 8 g\u002FdL\n  * Platelet Count ≥ 25 000\u002FµL\n  * Renal\n\n    ---Creatinine OR Measured or calculated creatinine clearance1 ≤ 1.5 × ULN OR\n\n    ≥ 30 mL\u002Fmin for participant with creatinine levels \\> 1.5 × institutional ULN\n  * Hepatic\n  * Bilirubin ≤ 1.5 ×ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels \\> 1.5 × ULN\n  * Aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN for participants with liver metastases)\n  * Alanine aminotransferase (ALT) ≤ 2.5 × ULN (≤ 5 × ULN for participants with liver metastases)\n  * Coagulation ---International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n* Females of childbearing potential must have a negative serum pregnancy test within 72 hours prior to registration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. See protocol for definition of childbearing potential.\n* Females of childbearing potential must be willing to abstain from heterosexual intercourse or to use an effective method(s) of contraception as outlined in protocol. Males must be willing to abstain from heterosexual intercourse or to use an effective method(s) of contraception as outlined in protocol.\n* Subjects with CNS disease are eligible so long as they meet all other eligibility criteria.\n* Patients must have a life expectancy of at least 6 months.\n* As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.\n\nExclusion Criteria:\n\n* Patients with a known history of Human Immunodeficiency Virus (HIV) infection are excluded. NOTE: No HIV testing is required unless mandated by local health authority.\n* Patients with concurrent active Hepatitis B (defined as HBsAg positive and\u002For detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection. NOTE: Hepatitis B and C screening tests are not required unless: (1) Known history of HBV and HCV infection or (2) As mandated by local health authority.\n* Patients previously treated with checkpoint blockade, including pembrolizumab, or mogamulizumab, are excluded.\n* Patients who have received disease radiation therapy within 7 days of C1D1.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to Cycle 1 Day 1. Systemic steroids at a dose less than the equivalent of 10 mg\u002Fday of prednisone and inhaled, nasal, and topical steroids are permitted as detailed in protocol.\n* Has active or prior autoimmune disease or inflammatory disorders that have required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs) with teh exception of vitiligo or alopecia. Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.\n* Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n* Known additional malignancy that is progressing or has required active treatment within the past 2 years. NOTE: patients with non-melanoma skin cancers and in situ cancers that do not require systemic therapies are eligible.\n* Active infection requiring systemic therapy.\n* Prior allogeneic stem cell transplant or allogeneic cellular therapies, recent immunosuppressive therapies (for any reason).\n* Prior solid organ transplant.\n* Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).\n* Has severe hypersensitivity (≥Grade 3) to pembrolizumab or mogamulizumab and\u002For any of their excipients.\n* Treatment with any investigational drug or investigation device within 30 days prior to registration.\n* Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines and mRNA or inactivated COVID-19 vaccine is allowed.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.",{"count":462,"type":22},23,[143],"This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1. For Cycle 2 and subsequent cycles, mogamulizumab will be administered on Day 1, 15 and 29 of each cycle. Subjects will undergo a response assessment prior to Cycle 3 and every 2 cycles thereafter.\n\nSubjects will continue study treatment until documented progression, unacceptable toxicity, or any other condition for discontinuation is met in protocol. A maximum of 2 years of study treatment may be administered. If a subject achieves a complete response (CR) per mSWAT criteria after 3 months of study treatment (2 cycles), they will continue study therapy for an additional 6 months (4 cycles). If a confirmed and persistent CR is met, they may discontinue study treatment and enter an observation period in protocol. Repeat disease evaluation is required prior to study therapy discontinuation. Subjects who progress during the observation period may be eligible for up to an additional 9 cycles (1 year) of pembrolizumab and mogamulizumab.",[466,467],"Cutaneous T Cell Lymphoma","Fungoides Mycosis Sezary Syndrome","2026-05-04",{"date":470,"type":35},"2026-05-05",{"date":472,"type":35},"2023-12-06",{"date":474,"type":22},"2027-12",{"name":41,"class":42},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":23,"phases":484,"briefSummary":485,"conditions":486,"keywords":488,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":495,"locationsCount":43},"100511874","prehabilitation-program-to-improve-cardiac-reserve-in-high-risk-patients-undergoing-hematopoietic-stem-cell-transplantation-100511874","NCT05945121","Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation","Cardio-Oncology Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Adult 18 years or older\n* Referred for HSCT evaluation\n* Presence of least one CV risk factor at enrollment (hypertension, hyperlipidemia, atrial fibrillation, obesity, heart failure, history of coronary artery disease, diabetes)\n* Able to ambulate unassisted\n* Ability to understand and the willingness to sign a written informed consent\n* Ability to use Polar Flow heart rate application\n\nExclusion Criteria:\n\n* Severe anemia (hemoglobin \\\u003C7 gm\u002Fdl)\n* Untreated high-risk coronary artery disease (left main, triple vessel disease)\n* Severe aortic stenosis\n* Recent fracture as assessed via self-report\n* Gross balance deficits\n* Severe pain with basic movement\n* Unable to ambulate unassisted or exercise\n* NYHA class IV heart failure\n* Adults unable to give consent, pregnant women, and prisoners are excluded from this study.",{"count":382,"type":22},[25],"To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.",[487],"Hematopoietic Stem Cell Transplant",[489],"Cardiovascular disease","2026-05-01",{"date":468,"type":35},{"date":493,"type":35},"2023-08-25",{"date":130,"type":22},{"name":41,"class":42},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":316,"minAge":18,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":23,"phases":505,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":94},"100563437","phase-1-ruxolitinib-and-enzalutamide-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer-100563437","NCT06616155","Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer","Study of JAK Inhibition in Stem-Like Prostate Cancer (JASPER): A Phase 1b\u002F2a Multicenter Study of Ruxolitinib and Enzalutamide in Castration Resistant Prostate Cancer","Inclusion Criteria:\n\n* Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information prior to registration\n* Males age ≥ 18 years with progressive metastatic, castration-resistant prostate cancer, previous adenocarcinoma histology confirmation required\n* Ability to understand a written informed consent document, as determined by the study physician or designee\n* Surgical castration or continuous medical castration ≥ 8 weeks prior to screening; serum testosterone \\\u003C 50 ng\u002FdL\n* Have progressed on prior abiraterone treatment by Prostate Cancer Working Group 3 prostate specific antigen (PSA) criteria\n\n  * PSA must rise on two measurements at least 1 week apart in order to be eligible. Refer to PCWG3 for clarification.\n  * Most Recent absolute PSA must be \\> 2.0 ng\u002FmL\n* Patient meets definition of poor responder to abiraterone by one of the following:\n\n  * Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting (abiraterone started within 4 months of starting continuous androgen deprivation therapy \\[ADT\\]): \\\u003C 12 months duration on abiraterone\n  * Abiraterone started in castration-resistant prostate cancer (CRPC) disease setting: \\\u003C 6 months duration on abiraterone due to progression or failure to achieve PSA50 response while on therapy\n* The patient's current or most recent treatment is ADT and abiraterone. Participants must sign consent within 30 days of discontinuing abiraterone or prior to stopping abiraterone\n* Patients must be willing to undergo metastatic tumor biopsy during screening. If no metastatic lesion is safely accessible to tumor biopsy, this requirement will not be required\n* 50% of patients must have measurable disease by RECIST 1.1 criteria\n\n  * Once 50% of total expected cohort has non-measurable disease, only patients with measurable disease by RECIST 1.1 criteria will be eligible. (Percentages with measurable disease are not relevant within dose escalation. Once dose expansion is started, those at expansion dose would be included in percentage evaluation.)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 (grade 2 ECOGs should be related to disease and thus potentially reversible)\n* A male participant must agree to use of contraception during the treatment period and for at least 90 days after the last dose of study drug. Female partners of male patients should also use contraception for 90 days after the last dose of study drug if they are of childbearing potential\n* Platelets ≥ 125,000\u002Fmm\\^3 (obtained within 28 days prior to starting study therapy) (if creatinine clearance \\[CrCl\\] is between 30-59, the platelet entry criteria is \\> 150,000\u002Fmm\\^3)\n* Absolute neutrophil count (ANC) ≥ 1500\u002Fmm\\^3 (obtained within 28 days prior to starting study therapy)\n* Hemoglobin ≥ 11 g\u002FdL (obtained within 28 days prior to starting study therapy) No transfusions within 90 days prior to screening unless performed for acute bleeding\n* Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN) (obtained within 28 days prior to starting study therapy) For patients with known liver metastasis: (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN\n* Bilirubin ≤ 1.5 the upper limit of normal (ULN) OR direct bilirubin ≤ ULN for participants with total bilirubin levels \\> 1.5 x ULN. For subjects with known Gilbert's disease, bilirubin ≤ 3.0 mg\u002FdL (obtained within 28 days prior to starting study therapy)\n* Creatinine clearance (CrCl) ≥ 30 mL\u002Fmin (obtained within 28 days prior to starting study therapy) For creatinine clearance estimation, the Cockcroft and Gault equation should be used\n\nExclusion Criteria:\n\n* History of untreated (with radiotherapy and\u002For surgery) brain metastasis is not allowed (stable and treated metastases are allowed)\n* History of seizures or known hypersensitivity to enzalutamide, ruxolotinib or any of the excipients in the product\n* Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with the absorption of the study medications\n* Uncontrolled hypertension as indicated by systolic blood pressure (SBP) \\> 170 mmHg or diastolic blood pressure (DBP) \\> 105 mmHg on 2 consecutive measurements at screening visit unless known to have white coat hypertension syndrome\n* Have received chemotherapy in the metastatic castration-resistant setting (docetaxel within the hormone sensitive setting is allowed)\n* Failure to recover to grade 1 or lower toxicity related to prior systemic therapy (excluding alopecia and neuropathy) prior to study consent\n* Current active infection with any of the following: hepatitis B, hepatitis C, active tuberculosis, latent tuberculosis. Patients with well controlled HIV are eligible however all drug interactions with HIV drug and study therapies have to be reviewed\n* History of myocardial infarction, stroke, pulmonary embolism or deep vein thrombosis within 6 months of study enrollment\n* Study physician estimates life expectancy less than 6 months or patient is unable to swallow medications\n* Patients currently taking fluconazole\n* Currently receiving supplements containing androgens or medications known to be strong inhibitors of CYP2C8, strong inducers (except enzalutamide) or strong inhibitors of CYP3A4 and substrates of CYP3A4, CYP2C9 and CYP2C19 with a narrow therapeutic window. If substitution is possible, strong inducers, inhibitors and substrates must be discontinued at least 7 days or 5 half-lives (which ever longer) prior to the first administration of enzalutamide\n* Due to risk of tuberculosis (TB) reactivation, patients deemed at high risk by treating provider (e.g., close contact with someone with active TB, history of active\u002Flatent TB) should be excluded\n* Those with underlying hepatic disease with a CHILD-PUGH class A, B or C impairment are excluded",{"count":504,"type":22},20,[168,143],"This phase I\u002FII tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that remains despite blocking hormone production (castration-resistant) and that has spread from where it first started to other places in the body (metastatic). Ruxolitinib, a kinase inhibitor, slows down the growth of the tumor by blocking the proteins, JAK1 and JAK2, tumors use to grow. Enzalutamide, an androgen receptor inhibitor, works by blocking the effects of androgen (a male reproductive hormone). This may help stop the growth and spread of tumor cells that need testosterone to grow. Giving ruxolitinib in combination with enzalutamide may be safe, tolerable, and\u002For effective in treating metastatic castration-resistant prostate cancer.",[508,509,510],"Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8","2026-04-30",{"date":470,"type":35},{"date":514,"type":22},"2026-06",{"date":516,"type":22},"2030-06",{"name":41,"class":42},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":273,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":23,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":43},"100627077","phase-2-a-dietary-supplement-resistant-potato-starch-for-reducing-musculoskeletal-symptoms-in-individuals-planning-to-receive-aromatase-inhibitor-therapy-aimss-rps-trial-100627077","NCT07443943","A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial","Phase 2 Study of Aromatase Inhibitor-Associated Musculoskeletal Symptom Prevention With Resistant Potato Starch (AIMSS-RPS)","AIMSS-RPS","Inclusion Criteria:\n\n* Patient who is planning to start standard-of-care AI therapy and receive treatment for at least 24 weeks. Can be planning to take AI therapy for stage 0-3 breast cancer or because they are at high risk of developing breast cancer. Concurrent gonadotropin-releasing hormone antagonist (GnRHa) therapy, anti-osteoclast therapy, anti-HER2 therapy, ribociclib, and\u002For PARP inhibitor are permitted\n* Average joint pain 0-6 on a 0-10 scale during the 7 days prior to study enrollment\n* Able to take oral medication\n* Able to read and understand English\n* Aware of the nature of her diagnosis, understands study requirement, and able to sign an informed consent form\n\nExclusion Criteria:\n\n* Distant metastatic breast cancer\n* Current or planned use of abemaciclib during study participation\n* Current or planned use of chemotherapy or immunotherapy during study participation\n* Pregnant or breast feeding, or planning to become pregnant during study participation\n* Known active inflammatory bowel disease\n* History of colectomy and\u002For gastric bypass\n* Prior AI therapy except in the context of fertility treatment\n* Planned use of prebiotics during study participation\n* Use of estrogen supplementation other than vaginal estrogen\n* Receipt of another investigational agent concurrent with participation in this trial",{"count":504,"type":22},[143],"This phase II trial tests the safety and effectiveness of a dietary supplement called resistant potato starch for reducing musculoskeletal symptoms in patients with stage 0-III breast cancer or who are at high risk for breast cancer and are planning to receive treatment with an aromatase inhibitor. Aromatase inhibitors are a type of drug commonly used for the treatment or prevention of breast cancer. Many people who receive aromatase inhibitors experience musculoskeletal symptoms (symptoms relating to bones and muscles, such as joint pain or stiffness). Research has shown there may be an association between reduced levels of beneficial gut bacteria and the development of aromatase inhibitor-associated musculoskeletal symptoms. Resistant potato starch is a plant-based low-digestible carbohydrate that has the potential to promote the growth of beneficial gut bacteria. Taking resistant potato starch while receiving aromatase inhibitor therapy may reduce musculoskeletal symptoms in patients with stage 0-III breast cancer or individuals at high risk of developing breast cancer.",[530,254,255,256,531],"Anatomic Stage 0 Breast Cancer AJCC v8","Localized Breast Carcinoma","2026-04-23",{"date":534,"type":35},"2026-04-24",{"date":536,"type":35},"2026-04-22",{"date":538,"type":22},"2028-04",{"name":41,"class":42},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":23,"phases":549,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":555,"leadSponsor":556,"locationsCount":43},"100629951","sunbeast-evaluating-uv-protective-behaviors-and-education-interventions-among-ultrarunners-100629951","NCT07481344","SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners","SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners at the Western States Endurance Run","Inclusion Criteria:\n\n* Must be 18 years or older\n* 2026 registered WSER runner\n* Understand English\n\nExclusion Criteria:\n\n* Not Applicable",{"count":548,"type":22},110,[25],"Participants will be randomly assigned to either the intervention or control group using concealed allocation. The intervention-comprising targeted educational materials and behavioral prompts-will be delivered over three months preceding race day.\n\nAll study participants will be required to complete the pre-race survey prior to the intervention. The intervention group will complete the SunBeast Educational module once and receive monthly reinforcement messages leading into race day. The SunBeast Educational Program module consists of a 30-minute live, interactive online discussion and infographics\u002Fvideos on skin cancer, UV index awareness, sunscreen use, protective clothing, and timing of runs. The control group will receive a general wellness brochure via email. The general wellness brochure will contain UV protection information but will also have other general wellness topics.",[552],"Sun Protection",{"date":534,"type":35},{"date":177,"type":22},{"date":177,"type":22},{"name":41,"class":42},""]